Subscribe to Angie's Blog

image

COVID-19 Vaccines and Treatments

  • AHCA/NCAL COVID-19 Facility Vaccine Clinic Checklist v1 (Created 12/14/20)
    AHCA/NCAL has created the checklist for use when administering vaccines.
  • AMDA Letter To Families COVID Vaccine (Released 12/23/20)
    The Society for Post-Acute and Long-Term Care Medicine have provided a letter that facilities can use to inform families about the safety of the COVID-19 vaccines.
  • AMDA - Q&A about the COVID-19 Vaccine for PALTC Patients Family Member and Staff Dec 1, 2020
    The Society for Post-Acute and Long-Term Care Medicine has released a Q&A about the COVID-19 vaccine.
  • Bamlanivimab EUA for COVID-19 v1 (Released 1/5/21)
    The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization. Eligibility for patients considered high risk.
  • CDC Advisory Committee on Immunization Practices v1 (Released 12/9/20)
    The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develops recommendations on how to use vaccines to control diseases in the United States. This document answers questions about the ACIP such as how it makes decisions about vaccine recommendations, what the ACIP considers in the vaccine recommendation process, and where you can find their vaccine recommendations.
  • CDC Facts about COVID-19 vaccines (Posted 1/8/21)
    A flyer from the CDC with facts about the COVID-19 vaccine
  • CDC Management of Anaphylaxis at COVID-19 Vaccination Site (Posted 12/28/20)
    Anaphylaxis is an acute and potentially life-threatening serious allergic reaction. Severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine or any component of the COVID-19 vaccine listed in the prescribing information is a contraindication to vaccination. A history of a severe allergic reaction to any other vaccine or injectable therapy is a precaution to vaccination.
  • CDC Pfizer COVID-19 Vaccine Standing Orders for Administering Vaccine (12/17/20)
    To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP)
  • CDC Pre-Vaccination Screening Form (Posted 12/28/20)
    The following questions will help us determine if there is any reason you should not get the COVID-19 vaccine on that particular day. If you answer “yes” to any question, it does not necessarily mean you should not be vaccinated. It just means additional questions may be asked.
  • CDC Product Information Guide for COVID-19 Vaccines v1 (Released 12/4/20)
    This guide provides specifications for COVID-19 vaccine and associated products. This is NOT a catalog from which you can order products. It provides key product information including product package dimensions and weight, minimum order quantities, product presentation, distribution method, storage information, and additional information. This guide will be updated as more products become available.
  • CDC Recommendations COVID Vaccine v1 (Released 12/22/20)
    On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine. The vaccine consists of 2 doses (30 μg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥ 16 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework, using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP’s interim recommendations for allocating initial supplies of COVID-19 vaccines. The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.
  • CDC V-Safe Registration Information (Posted 12/28/20)
    V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccination. Through v-safe, you can quickly tell CDC if you have any side effects after getting the COVID-19 vaccine. Depending on your answers, someone from CDC may call to check on you and get more information. And v-safe will remind you to get your second COVID-19 vaccine dose if you need one.
  • CDC Resident Vaccine FAQs (Posted 1/8/21)
    CDC has provided frequently asked questions and answers especially for LTCF residents and their families to help everyone understand the importance of COVID-19 vaccination.
  • CDC Staff Vaccine FAQs (Posted 1/8/21)
    You are on the front lines and risk being exposed to COVID-19 each day on the job. Early vaccination can protect not only you from getting sick, but also help protect residents and your family members who may have underlying health conditions that put them at risk for severe illness from COVID-19. The CDC has answers to some of the questions you have.
  • CDC What to Expect After Vaccine (Posted 1/8/21)
    COVID-19 vaccination will help protect you from getting COVID-19. You may have some side effects, which are normal signs that your body is building protection. These side effects may feel like flu and may even affect your ability to do daily activities, but they should go away in a few days.
  • CMS Toolkit on State Actions to Mitigate COVID-19 Prevalence in Nursing Homes - v 13 NOV 2020
    This toolkit catalogs the many innovative solutions designed at the state level to protect our nation’s vulnerable nursing home residents during the Coronavirus disease 2019 (COVID-19) pandemic. Beginning in October 2020, the toolkit includes up-to-date information, guidance, and innovative programs designed to increase vaccine use against influenza virus, pneumococcus (bacterium), and SARS-CoV-2, the virus that causes COVID-19.
  • COVID Vaccines Q&A from MedScape v1 (Released 1/20/21)
    COVID-19 Vaccines Questions and Answers
  • COVID Vaccine Toolkit v3 (Released 1/22/21)
    We've put together a toolkit of the policies and procedures you need when implementing your COVID vaccine program.
  • COVID-19 Non-Mandatory Vaccine Policy & Procedure v1 (Released 12/11/20)
    A policy & procedure for those communities that are making the COVID-19 vaccine voluntary.
  • COVID-19 Post-Discharge Acknowledgement v1 (Released 12/21/20)
    Use this acknowledgment for residents who received the first dose of the two-part vaccine, and acknowledge that it is their responsibility to contact CVS or Walgreens to schedule their second dose.
  • COVID-19 Post-Discharge Acknowledgement - Spanish v1 (Released 12/23/20)
    Use this acknowledgment for residents who received the first dose of the two-part vaccine, and acknowledge that it is their responsibility to contact CVS or Walgreens to schedule their second dose. (Spanish version)
  • COVID-19 Vaccination Exemption Request v1 (Released 12/11/20)
    If a COVID-19 vaccine can be made mandatory, exemptions will likely exist. Use this form for those situations.
  • COVID-19 Vaccination Exemption Request - Spanish v1 (Released 12/16/20)
    If a COVID-19 vaccine can be made mandatory, exemptions will likely exist. Use this form for those situations. (Spanish version)
  • COVID-19 Vaccination Toolkit v2 (Released 12/21/20)
    We've combined our latest policies and procedures and forms about the COVID-19 vaccination into one toolkit. We will update this toolkit as more information becomes available.
  • Emergency Use Authorization v1 (Released 12/9/20)
    The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against CBRN threats by facilitating the availability and use of MCMs (medical countermeasures) needed during public health emergencies.